期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 69, 期 12, 页码 2513-2522出版社
SPRINGER
DOI: 10.1007/s00262-020-02637-1
关键词
Neutrophil to lymphocyte ratio (NLR); NLR variation; Anti-PD1; Nivolumab; Renal cell carcinoma; Non-small cell lung cancer
Background An elevated pre-treatment neutrophil to lymphocytes ratio (NLR) is associated with poor prognosis in various malignancies. Optimal cut-off is highly variable across studies and could not be determined individually for a patient to inform his prognosis. We hypothesize that NLR variations could be more useful than baseline NLR to predict progression-free survival (PFS) and overall survival (OS) in patients (pts) receiving anti-PD1 treatment. Patients and methods All pts with metastatic renal cell carcinoma (mRCC) and metastatic non-small cell lung cancer (mNSCLC) who received anti-PD1 nivolumab monotherapy in second-line setting or later were included in this French multicentric retrospective study. NLR values were prospectively collected prior to each nivolumab administration. Clinical characteristics were recorded. Associations between baseline NLR, NLR variations and survival outcomes were determined using Kaplan-Meier's method and multivariable Cox regression models. Results 161 pts (86 mRCC and 75 mNSCLC) were included with a median follow-up of 18 months. On the whole cohort, any NLR increase at week 6 was significantly associated with worse outcomes compared to NLR decrease, with a median PFS of 11 months vs 3.7 months (p< 0.0001), and a median OS of 28.5 months vs. 18 months (p= 0.013), respectively. In multivariate analysis, NLR increase was significantly associated with worse PFS (HR 2.2;p = 6.10(-5)) and OS (HR 2.1;p = 0.005). Consistent results were observed in each cohort when analyzed separately. Conclusion Any NLR increase at week 6 was associated with worse PFS and OS outcomes. NLR variation is an inexpensive and dynamic marker easily obtained to monitor anti-PD1 efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据